2. Antibody-drug Conjugate/ADC Related
  3. Antibody-Drug Conjugates (ADCs)
  4. Sirtratumab vedotin

Sirtratumab vedotin  (Synonyms: AGS15E; ASG-15ME; 1vcMMAE)

Cat. No.: HY-P99595 Purity: 97.38%
COA
SDS
Handling Instructions Technical Support

Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Sirtratumab vedotin

Sirtratumab vedotin 화학구조

CAS No. : 1824663-83-3

사이즈 가격 재고 수량
1 mg 해외재고보유
5 mg 해외재고보유
10 mg 해외재고보유
50 mg   견적 받기  
100 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 Customer Validation

Sirtratumab vedotin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1].

In Vitro

Sirtratumab vedotin (ASG15-ME) shows high-affinity binding to SLITRK6 expressed on SW780 cells with a Kd of 0.018 nM[1].
Sirtratumab vedotin (10 μg/mL; 1 h) internalizes after binding to SLITRK6[1].
Sirtratumab vedotin (120 h) inhibits CHP-212 cell survival with an IC50 of 0.99 nM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sirtratumab vedotin Related Antibodies

Cell Viability Assay[1]

Cell Line: CHP-212 and IGR-OV1 cells
Concentration:
Incubation Time: 120 h
Result: Showed a dose-dependent inhibition of CHP-212 cell survival with an IC50 of 0.99 nM. Had no effect on IGR-OV1 cells (SLITRK6 negative) when applied at the same concentrations.
In Vivo

Sirtratumab vedotin (ASG15-ME; 0.25-5 mg/kg; i.v.; 2x per week for 2 or 3 weeks or single dose) shows potent antitumor activity in multiple xenograft models in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID mice, RT4 xenograft model[1]
Dosage: 5 mg/kg
Administration: Intravenous injection, single dose
Result: Caused significant inhibition.
Animal Model: SCID mice, AG-B7 and AG-B8 xenograft model[1]
Dosage: 0.25 and 0.5 mg/kg
Administration: Intravenous injection, 2x per week for 2 or 3 weeks
Result: Significantly reduced tumor volume.
Animal Model: SCID mice, the lung xenograft model NCI-H322M[1]
Dosage: 3 mg/kg
Administration: Intravenous injection, 2x per week for 3 weeks
Result: Was able to cause 99% tumor growth inhibition.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Sirtratumab vedotin]
선적

Shipping with dry ice.
보관

-80°C, protect from light
순도&문서

Purity: 97.38%

SDS (251 KB)

COA (230 KB) Others (126 KB) SEC-HPLC (89 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sirtratumab vedotin Related Classifications

  • 몰농도 계산기

  • 농도 희석 계산기

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sirtratumab vedotin1824663-83-3AGS15E ASG-15ME 1vcMMAEAntibody-Drug Conjugates (ADCs)Antibody-Drug ConjugatesSCID miceCHP-212RT4AG-B7AG-B8NCI-H322MInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Sirtratumab vedotin
Cat. No.:
HY-P99595
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.